ERBB2 and breast carcinoma: Finally, doxorubicin-loaded liposomes coated with trastuzumab and OKT-3, an anti-CD3 monoclonal antibody, have also been developed, demonstrating a higher cytotoxic effect than non-coated liposomes in HER-2-positive breast cancer cells (BT474 cells).